Chemotherapy News and Research

Latest Chemotherapy News and Research

RhoC gene promotes breast cancer stem cell progression

Researchers at the University of Michigan Comprehensive Cancer Center have found that a cancer gene linked to aggressive spread of the disease promotes breast cancer stem cells. The finding implies a new way to target the behavior of these lethal cells.

25 Jul 2012

New algorithm can help scientists predict gene and drug interactions

Researchers from Mount Sinai School of Medicine have developed a new computational method that will make it easier for scientists to identify and prioritize genes, drug targets, and strategies for repositioning drugs that are already on the market. By mining large datasets more simply and efficiently, researchers will be able to better understand gene-gene, protein-protein, and drug/side-effect interactions. The new algorithm will also help scientists identify fellow researchers with whom they can collaborate.

25 Jul 2012

Study identifies MDM4 protein as promising target for treatment of melanoma

A melanoma is a malignant form of skin cancer and is one of the most aggressive types of tumors there is. Treatment is particularly difficult, because melanomas are usually resistant against conventional chemotherapy treatments.

24 Jul 2012

VEGF inhibitor fails to improve nonsquamous NSCLC overall survival

Adding motesanib to carboplatin–paclitaxel does not boost overall survival in patients with advanced nonsquamous non-small-cell lung cancer, including those with adenocarcinoma, say MONET1 investigators.

24 Jul 2012

Stromal cells offer chemotherapy clue in early lung cancer

Podoplanin-positive cancer-associated fibroblasts predict recurrence in stage I lung adenocarcinoma, which could help identify patients suited for adjuvant chemotherapy, research shows.

24 Jul 2012

OncoSec announces data from two Phase III trials of OMS ElectroChemotherapy for SCCHN

OncoSec Medical Inc., a company developing the advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumors, announced data from an interim analysis of two randomized Phase III clinical trials, HNBE-01 and HNBE-02, using electrochemotherapy to treat locally recurrent and second primary squamous cell carcinoma of the head and neck.

24 Jul 2012

Study represents new use of bone marrow transplantation

Researchers at Fred Hutchinson Cancer Research Center have opened a clinical trial to test the theory that giving a patient a new immune system can cure severe cases of Crohn's disease, a chronic inflammatory condition of the gastrointestinal tract.

24 Jul 2012

Roundup: Plan for new Md. hospital advances; Outsourcing of prison health care gets scrutiny; Alaska Native medical center seen as model

Maryland officials are preparing to unveil this week a detailed plan for a $600 million regional hospital to replace the ailing Prince George's Hospital Center and establish a new health-care network throughout Prince George's County. The plans are part of a broad effort to improve health care in a county where an estimated 150,000 residents lack health insurance or have insufficient coverage and often rely on hospital emergency rooms for primary care.

24 Jul 2012

Bioniche receives U.S. and Canadian approval for first of two canine oncology products

Bioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company, today announced that the first of two canine oncology products has received approval by regulators in both the U.S. and Canada.

24 Jul 2012

Neural precursor cells suppress aggressive tumors

Neural precursor cells (NPC) in the young brain suppress certain brain tumors such as high-grade gliomas, especially glioblastoma (GBM), which are among the most common and most aggressive tumors.

23 Jul 2012

Berg Pharma initiates BPM 31543 clinical trial for chemotherapy-induced alopecia

Berg Pharma, a Boston-based pharmaceutical company focused on discovery and development of new treatments in cancer and metabolic diseases, announced the initiation of a clinical trial entitled "Phase I Dose-Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of a Topical Compound 31543 in Adult Patients Receiving Chemotherapy for the Treatment of Breast Cancer."

23 Jul 2012

Bayer, Onyx and Astellas announce results from Tarceva plus Nexavar Phase 3 trial on HCC

Bayer HealthCare Pharmaceuticals, Onyx Pharmaceuticals, Inc., and Astellas Pharma Inc. today announced that a Phase 3 trial evaluating the efficacy and safety of the addition of Tarceva (erlotinib) tablets to Nexavar (sorafenib) tablets did not improve overall survival for patients with unresectable hepatocellular carcinoma (HCC) vs. Nexavar alone.

23 Jul 2012

Researchers identify several gene mutations responsible for medulloblastoma

Researchers at the Stanford University School of Medicine and Lucile Packard Children's Hospital have identified several gene mutations responsible for the most common childhood brain tumor, called medulloblastoma, adding evidence to the theory that the diagnosis is a group of genetically distinct cancers with different prognoses. These and accompanying findings are likely to lead to less-toxic, better-targeted treatment approaches over the next two years, the researchers said.

23 Jul 2012

Researchers link specific gene mutations with four recognized subtypes of medulloblastoma

Researchers at Dana-Farber/Children's Hospital Cancer Center (DF/CHCC) and several collaborating institutions have linked mutations in specific genes to each of the four recognized subtypes of medulloblastoma, the most common malignant brain tumor of children. The discovery, reported July in the journal Nature, provides doctors with potential biomarkers for guiding and individualizing treatment and reveals prospective therapeutic opportunities for countering this devastating malignancy.

23 Jul 2012

International Congress on Natural Products Research to be held in New York City

The urgent need to evaluate nature's repository of chemicals in plants, microbes, and marine organisms for their potential value in health care will be a major theme of a five-day scientific conference in New York that is expected to draw some 1,200 natural products researchers from around the world.

21 Jul 2012

EMA CHMP issues positive opinion for conditional approval of brentuximab vedotin for lymphoma

Millennium: The Takeda Oncology Company and, Takeda Pharmaceutical Company Limited today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion for conditional approval of brentuximab vedotin for two indications.

21 Jul 2012

Janssen-Cilag receives positive opinion from EMA CHMP for DACOGEN

Janssen-Cilag International NV announced today that the Committee for Medical Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion recommending approval of DACOGEN (decitabine) for Injection.

21 Jul 2012

Marshall University faculty member receives $426,000 NIH grant for lung cancer study

A Marshall University faculty member has been awarded a three-year, $426,000 grant by the National Institutes of Health (NIH) to further her lung cancer research.

21 Jul 2012

Actinium completes Actimab-A Phase I/II study on Acute Myeloid Leukemia

Actinium Pharmaceuticals, Inc. a biotechnology company focused on developing innovative, alpha particle radiotherapy targeted cancer treatments addressing major unmet medical needs, today announced that it has successfully treated the first cohort of patients in a Phase I/II study of Actimab-A in Acute Myeloid Leukemia (AML) clinical trial. Patients were treated at Memorial Sloan Kettering Cancer Center in New York City.

20 Jul 2012

Patients, partners affected by colorectal cancer course

Partners of individuals with colorectal cancer, as well as the patients themselves, are at risk for psychologic morbidity according to the type of treatment given, show Portuguese study results.

19 Jul 2012

Chemotherapy News and Research

Latest Chemotherapy News and Research

RhoC gene promotes breast cancer stem cell progression

New algorithm can help scientists predict gene and drug interactions

Study identifies MDM4 protein as promising target for treatment of melanoma

VEGF inhibitor fails to improve nonsquamous NSCLC overall survival

Stromal cells offer chemotherapy clue in early lung cancer

OncoSec announces data from two Phase III trials of OMS ElectroChemotherapy for SCCHN

Study represents new use of bone marrow transplantation

Roundup: Plan for new Md. hospital advances; Outsourcing of prison health care gets scrutiny; Alaska Native medical center seen as model

Bioniche receives U.S. and Canadian approval for first of two canine oncology products

Neural precursor cells suppress aggressive tumors

Berg Pharma initiates BPM 31543 clinical trial for chemotherapy-induced alopecia

Bayer, Onyx and Astellas announce results from Tarceva plus Nexavar Phase 3 trial on HCC

Researchers identify several gene mutations responsible for medulloblastoma

Researchers link specific gene mutations with four recognized subtypes of medulloblastoma

International Congress on Natural Products Research to be held in New York City

EMA CHMP issues positive opinion for conditional approval of brentuximab vedotin for lymphoma

Janssen-Cilag receives positive opinion from EMA CHMP for DACOGEN

Marshall University faculty member receives $426,000 NIH grant for lung cancer study

Actinium completes Actimab-A Phase I/II study on Acute Myeloid Leukemia

Patients, partners affected by colorectal cancer course

Cancer Research - Second Edition eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in